Long-term care of Parkinson's disease: Strategies for managing "wearing off" symptom re-emergence and dyskinesias

Geriatrics

Volumn 61, Issue 9, 2006, Pages 14-20

  Hauser, Robert ^a,b  

^a Pharmacology and Experimental Therapeutics   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Caregiver burden; Continuous dopaminergic stimulation; Levodopa carbidopa; Long term care; Parkinson's disease; Treatment

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RISPERIDONE; ROPINIROLE; SELEGILINE;

ADULT; AGED; CHOREA; COMORBIDITY; CONFUSION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DYSKINESIA; FAMILY; GERIATRIC CARE; HALLUCINATION; HUMAN; HYPOTENSION; LONG TERM CARE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PATIENT EDUCATION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY;

ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; LONG-TERM CARE; PARKINSON DISEASE;

EID: 33748940420     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Center for Disease Control, National Center for Health Statistics. NCHS Data on Parkinson's Disease. Available at: http://www.parkinson.org/site/pp.asp? c=9dJ FJLPwB&b=71125&printmode=1. Accessed Aug. 28, 2006.
2. Lapane KL, Fernandez HH, Friedman JH, and the SAGE Study Group. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. Pharmacotherapy 1999; 19(11)11321-7.
3. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991:1-14.
4. Colcher A, Simuni T. Clinical manifestations of Parkinson's disease. Med Clin North Am 1999; 83(2):327-47.
5. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol 2002; 9 Suppl 3:23-30.
6. Riley DE. Secondary parkinsonism. In: Parkinson's Disease and Movement Disorders. Eds. Jankovic, J.J., Tolosa, E. In: Janovic JJ, Tolosa E, editors. Parkinson's Disease and Movement Disorders. Philadelphia, PA: Lippincott Williams & Wilkins, 2002: 199-211.
7. Pal PK, Samii A, Calne DB. Cardinal features of early Parkinson's Disease. In: Factor SA, Weiner WJ, editors. Parkinson's Disease. Diagnosis and Clinical Management. Demos Medical Publishing, Inc. New York, NY: Demos Medical Publishing, Inc., 2002: 41-56.
8. Obeso JA, Linazasoro G, Gorospe A, Rodriguez MC, Lera G. Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow CW, Obeso JA, editors. Beyond the Decade of the Brain. Kent, UK: Wells Medical Limited, 1997: 11-37.
9. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39(1):37-45.
10. Suchowersky O. Parkinson's disease: medical treatment of moderate to advanced disease. Curr Neurol Neurosci Rep 2002; 2(4):310-6.
11. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006; 7(10):1399-407.
12. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 2003; 60(1):91-6.
13. Carter JH, Stewart BJ, Archbold PG, et al and the Parkinson's Study Group. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 1998; 13(1):20-8.
14. Caap-Ahlgren M, Dehlin O. Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients. Aging Clin Exp Res 2002; 14(5):371-7.
15. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48(8):938-42.
16. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson's disease using the minimum data set. Parkinsonism Relat Disord 2002; 8(5):369-80.
17. Longterm care for people with Parkinson's. United Kingdom Parkinson's Disease Society. Available at: http://www.parkinsons.org.uk/Templates/Int ernal.asp?NodeID=968940. Accessed March 10, 2005.
18. American Medical Directors Association. Parkinson's Disease in the long-term care setting. Columbia MD: American Medical Directors Association. 2002.
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 (Pt 5):2283-301.
20. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339(15):1044-53.
21. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990; 66(5):317-23.
22. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(Suppl 5):S1-S88.
23. Swope DM. Rapid treatment of "wearing off" in Parkinson's disease. Neurology 2004; 62(6 Suppl 4):S27-S31.
24. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2(8):577-88.
25. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005; 20(11):1397-404.
26. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8):1296-310.
27. Hammerstad JP, Woodward WR, Nutt JG, Gancher ST, Block GA, Cyhan G. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994; 17(5):429-34.
28. Sinemet CR [package insert]. Whitehouse Station, NJ: Merck; 2002.
29. Olanow CW, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000; 23(Suppl):S117-S126.
30. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62(1 Suppl 1):S64-S71.
31. Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off. (Simcom Study). Acta Neurol Scand 2006; 114(3):181.
32. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41(4):261-309.
33. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20(6):726-33.